<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 ACR VEXAS Syndrome Guidelines - Interactive Cases</title>
    <style>
        /* Color Palette
        Deep Navy: #17375E
        Teal: #3998A5
        Gold: #B59449
        Light Gray: #F3F4F6
        White: #FFFFFF
        */

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: #F3F4F6; /* Light Gray Background */
            min-height: 100vh;
            padding: 20px;
            line-height: 1.7;
            color: #333333; /* Default text color */
        }

        .container {
            max-width: 900px;
            margin: 40px auto;
            background: #FFFFFF; /* White container */
            border-radius: 12px;
            box-shadow: 0 10px 30px rgba(23, 55, 94, 0.1); /* Subtle Navy shadow */
            overflow: hidden;
        }

        .header {
            background: #17375E; /* Deep Navy */
            color: white;
            padding: 30px;
            text-align: center;
        }

        .header h1 {
            font-size: 2rem;
            margin-bottom: 10px;
        }

        .header p {
            opacity: 0.9;
            font-size: 1.1rem;
        }

        .case-selector {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 15px;
            padding: 25px;
            background: #F9FAFB; /* Slightly off-white */
            border-bottom: 1px solid #E5E7EB;
        }
        
        .resource-links {
            display: flex;
            justify-content: center;
            gap: 15px;
            padding: 20px;
            background: #F9FAFB;
            border-bottom: 1px solid #E5E7EB;
            flex-wrap: wrap;
        }

        .case-btn, .resource-btn {
            padding: 12px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-size: 0.95rem;
            font-weight: 600;
            transition: all 0.3s ease;
            text-align: center;
            border: none;
        }
        
        .case-btn {
            background: #FFFFFF;
            border: 2px solid #3998A5; /* Teal Border */
            color: #17375E; /* Navy Text */
        }

        .case-btn:hover {
            background: #3998A5; /* Teal Background */
            color: white;
            transform: translateY(-2px);
            box-shadow: 0 5px 15px rgba(57, 152, 165, 0.3);
        }

        .case-btn.active {
            background: #3998A5;
            color: white;
            border-color: #3998A5;
        }

        .case-btn.completed {
            background: #059669; /* Keep green for completion */
            color: white;
            border-color: #059669;
        }
        
        .resource-btn {
            background: #17375E; /* Navy */
            border: 2px solid #17375E;
            color: white;
            min-width: 160px;
        }
        
        .resource-btn:hover {
            background: #1e4a7b;
            border-color: #1e4a7b;
            transform: translateY(-2px);
        }

        .content {
            padding: 30px;
            min-height: 500px;
        }

        .case-intro {
            background: #F3F4F6; /* Light Gray */
            border-left: 5px solid #3998A5; /* Teal Accent */
            padding: 20px;
            margin-bottom: 30px;
            border-radius: 5px;
        }

        .case-intro h2 {
            color: #17375E; /* Navy */
            margin-bottom: 15px;
        }

        .patient-info {
            background: #FFFFFF;
            border: 1px solid #E5E7EB;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }

        .patient-info h3 {
            color: #17375E;
            margin-bottom: 10px;
            font-size: 1.1rem;
        }

        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 10px;
            margin-top: 10px;
        }

        .info-item {
            padding: 8px;
            background: #F9FAFB;
            border-radius: 5px;
        }

        .info-item strong {
            color: #3998A5; /* Teal */
        }

        .visit-section {
            background: #FFFFFF;
            border: 1px solid #E5E7EB;
            border-radius: 10px;
            padding: 25px;
            margin: 20px 0;
        }

        .visit-header {
            background: #3998A5; /* Teal */
            color: white;
            padding: 15px;
            border-radius: 8px;
            margin-bottom: 20px;
        }

        .clinical-data {
            background: #F3F4F6; /* Light Gray */
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
            border: 1px solid #E5E7EB;
        }
        
        /* Ensure lists inside clinical data and feedback have margins */
        .clinical-data ul, .feedback ul, .key-points ul {
            margin-left: 20px;
            list-style-type: disc;
        }
        .clinical-data li, .feedback li, .key-points li {
            margin-bottom: 5px;
        }

        /* Light Teal background for question box */
        .question-box {
            background: #e6f5f7; 
            border: 2px solid #3998A5; /* Teal border */
            border-radius: 10px;
            padding: 20px;
            margin: 25px 0;
        }

        .question-box h4 {
            color: #17375E; /* Navy */
            margin-bottom: 15px;
            font-size: 1.2rem;
        }

        .question-note {
            color: #17375E;
            font-style: italic;
            margin-bottom: 10px;
            font-size: 0.95rem;
            opacity: 0.8;
        }

        .options {
            margin: 20px 0;
        }

        .option {
            display: block;
            width: 100%;
            text-align: left;
            padding: 15px;
            margin: 10px 0;
            background: #FFFFFF;
            border: 2px solid #E5E7EB;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.3s ease;
            font-size: 1rem;
            color: #333333;
        }

        /* Ensure hover effects only apply when not disabled */
        .option:hover:not(:disabled) {
            background: #f0f9fb;
            border-color: #3998A5; /* Teal */
            transform: translateX(5px);
        }

        .option.selected {
            background: #d0ebef; /* Lighter Teal */
            border-color: #3998A5; /* Teal */
        }

        /* Keep feedback colors standard (Green/Red) */
        .option.correct {
            background: #D1FAE5;
            border-color: #10B981;
            color: #065F46;
            cursor: default;
        }

        .option.incorrect {
            background: #FEE2E2;
            border-color: #EF4444;
            color: #991B1B;
            cursor: default;
        }

        .submit-btn {
            padding: 12px 30px;
            background: #3998A5; /* Teal */
            color: white;
            border: none;
            border-radius: 8px;
            cursor: pointer;
            font-size: 1.1rem;
            font-weight: 600;
            transition: all 0.3s ease;
        }

        /* Ensure hover effects only apply when not disabled */
        .submit-btn:hover:not(:disabled) {
            background: #2d7a85;
            transform: translateY(-2px);
            box-shadow: 0 5px 15px rgba(57, 152, 165, 0.4);
        }

        .submit-btn:disabled {
            background: #94a3b8;
            cursor: not-allowed;
            transform: none;
            box-shadow: none;
        }

        .feedback {
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
            display: none;
        }

        .feedback.correct {
            background: #D1FAE5;
            border: 2px solid #10B981;
            color: #065F46;
        }

        .feedback.incorrect {
            background: #FEE2E2;
            border: 2px solid #EF4444;
            color: #991B1B;
        }

        .feedback.partial {
            background: #FEF3C7;
            border: 2px solid #FBBF24;
            color: #92400E;
        }

        .feedback h5 {
            margin-bottom: 10px;
            font-size: 1.2rem;
        }

        .next-btn {
            padding: 12px 30px;
            background: #17375E; /* Navy */
            color: white;
            border: none;
            border-radius: 8px;
            cursor: pointer;
            font-size: 1.1rem;
            font-weight: 600;
            margin-top: 20px;
            transition: all 0.3s ease;
            display: none;
        }

        .next-btn:hover {
            background: #1e4a7b;
            transform: translateY(-2px);
        }

        .case-complete {
            background: #17375E; /* Navy */
            color: white;
            padding: 30px;
            border-radius: 15px;
            text-align: center;
            margin: 30px 0;
            display: none;
        }

        .case-complete h3 {
            font-size: 2rem;
            margin-bottom: 20px;
        }

        .score-display {
            font-size: 1.5rem;
            margin: 20px 0;
        }

        .final-feedback {
            background: #FFFFFF;
            color: #333333;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
            text-align: left;
            border: 1px solid #E5E7EB;
        }

        .final-feedback h4 {
            color: #17375E;
        }

        .key-points {
            background: #F3F4F6;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
            border: 1px solid #E5E7EB;
        }

        .key-points h4 {
            color: #3998A5; /* Teal */
            margin-bottom: 10px;
        }

        .key-points li {
            margin: 8px 0;
        }

        .welcome {
            text-align: center;
            padding: 50px 20px;
        }

        .welcome h2 {
            color: #17375E;
            margin-bottom: 20px;
            font-size: 2rem;
        }

        .welcome p {
            color: #555555;
            font-size: 1.1rem;
            margin-bottom: 30px;
        }

        /* Highlight using Gold */
        .highlight {
            background: #fdf6e9; /* Light Gold bg */
            color: #17375E; /* Navy text */
            padding: 2px 6px;
            border-radius: 3px;
            font-weight: 600;
            border: 1px solid #B59449; /* Gold border */
        }

        .critical {
            color: #DC2626;
            font-weight: bold;
        }

        /* Styling for guideline references using Teal */
        .new-guideline {
            background: #e6f5f7; /* Light Teal */
            border-left: 4px solid #3998A5; /* Teal Accent */
            padding: 10px 15px;
            margin: 15px 0;
            border-radius: 5px;
            color: #17375E;
        }

        .new-guideline strong {
            color: #17375E;
        }

        .lab-value {
            font-family: monospace;
            background: #E5E7EB;
            padding: 2px 5px;
            border-radius: 3px;
            color: #17375E; /* Navy */
            font-weight: bold;
        }

        /* Clinical note using Gold/Beige */
        .clinical-note {
            background: #fdf6e9;
            border: 1px solid #B59449;
            padding: 10px;
            margin: 15px 0;
            border-radius: 5px;
            color: #333333;
            font-style: italic;
        }

        @media (max-width: 768px) {
            .case-selector {
                grid-template-columns: 1fr;
            }
            .case-btn, .resource-btn {
                width: 100%;
            }
            .header h1 {
                font-size: 1.5rem;
            }
            .content {
                padding: 15px;
            }
            body {
                padding: 10px;
            }
            .container {
                margin: 10px auto;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>2025 ACR VEXAS Syndrome Guidelines</h1>
            <p>Interactive Case-Based Learning for Internal Medicine Residents</p>
        </div>

        <div class="case-selector">
            <button class="case-btn" onclick="selectCase(1)">Case 1: Classic Inflammatory</button>
            <button class="case-btn" onclick="selectCase(2)">Case 2: Hematologic/MDS</button>
            <button class="case-btn" onclick="selectCase(3)">Case 3: Diagnostic Challenges</button>
        </div>
        
        <div class="resource-links">
            <button class="resource-btn" onclick="openLink('https://www.nejm.org/doi/full/10.1056/NEJMoa2026834')">NEJM Original Paper (2020)</button>
            <!-- Note: The 2025 guideline link below is based on the DOI provided in the prompt context -->
            <button class="resource-btn" onclick="openLink('https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43287')">2025 ACR Guidelines</button>
            <button class="resource-btn" onclick="openLink('https://www.niams.nih.gov/labs/grayson-lab/vexas')">NIH VEXAS Resource</button>
        </div>

        <div class="content" id="content">
            <!-- Initial Welcome Screen -->
            <div class="welcome">
                <h2>Welcome to the VEXAS Syndrome Training Module</h2>
                <p>Select a case above to begin. Each case presents complex scenarios incorporating the 2025 ACR Guidance Statement for VEXAS Syndrome.</p>
                <p>You'll make clinical decisions at critical points and receive detailed feedback based on the new recommendations.</p>
                <div class="key-points" style="max-width: 600px; margin: 30px auto;">
                    <h4>VEXAS Overview</h4>
                    <ul style="text-align: left;">
                        <li><strong>V</strong>acuoles, <strong>E</strong>1 enzyme, <strong>X</strong>-linked, <strong>A</strong>utoinflammatory, <strong>S</strong>omatic</li>
                        <li>Caused by somatic mutations in UBA1 gene</li>
                        <li>Affects males >50 years (rare in females)</li>
                        <li>Inflammatory + Hematologic manifestations</li>
                        <li>High morbidity and mortality</li>
                    </ul>
                </div>
            </div>
        </div>
    </div>

    <script>
        // Global variables
        let currentCase = null;
        let currentVisit = 0;
        let score = 0;
        let totalQuestions = 0;
        let completedCases = new Set();
        let selections = {}; // Object to store selections for the current visit

        // Case data structure - Fully restored and verified
        const cases = {
            1: {
                title: "Case 1: The Classic Inflammatory Phenotype",
                patient: {
                    name: "68-year-old Male",
                    age: 68,
                    gender: "Male",
                    comorbidities: ["Hypertension", "Hyperlipidemia"],
                    medications: "Antihypertensives, Statin"
                },
                visits: [
                    {
                        title: "Visit 1: Initial Presentation",
                        scenario: `<strong>Chief Complaint:</strong> Recurrent fevers, fatigue, and painful ear swelling.
                        <br><br>
                        <strong>HPI:</strong> Presents with 6 months of intermittent, migratory arthralgias and profound fatigue. Over the last 4 weeks, he developed recurrent episodes of acute, severe pain and swelling of his left ear cartilage, sparing the lobe, accompanied by fevers (up to 101.5°F). He was treated twice with antibiotics for presumed cellulitis/perichondritis without improvement. He also reports new, painful red nodules on his shins.
                        <br><br>
                        <strong>Vitals:</strong> T 100.8°F (38.1°C), HR 98, BP 135/85, RR 16, SpO2 98% on RA.
                        <br><br>
                        <strong>Physical Exam:</strong>
                        <ul>
                            <li>General: Appears fatigued.</li>
                            <li>HEENT: Left auricle is erythematous, edematous, and exquisitely tender; the earlobe is spared.</li>
                            <li>MSK: Mild synovitis in the right wrist.</li>
                            <li>Skin: Multiple tender, erythematous subcutaneous nodules on bilateral lower extremities (consistent with erythema nodosum).</li>
                        </ul>
                        <br>
                        <strong>Initial Labs:</strong>
                        <ul>
                            <li>CBC: WBC 9.5 k/uL, Hgb <span class="lab-value">10.5</span> g/dL (Baseline 13.0), MCV <span class="lab-value">108</span> fL, Platelets 140 k/uL.</li>
                            <li>CMP: Normal.</li>
                            <li>Inflammatory Markers: CRP <span class="lab-value">120</span> mg/L (High), ESR <span class="lab-value">85</span> mm/hr (High).</li>
                        </ul>`,
                        questions: [
                            {
                                text: "Diagnostic Pause: Based on the history, physical exam, and initial laboratory findings, which of the following diagnoses should be strongly considered?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Granulomatosis with Polyangiitis (GPA)",
                                    "B. Relapsing Polychondritis (RP)",
                                    "C. VEXAS Syndrome",
                                    "D. Polyarteritis Nodosa (PAN)",
                                    "E. Disseminated infection (e.g., endocarditis)"
                                ],
                                correct: [1, 2, 4], // B, C, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Relapsing Polychondritis (RP):</strong> Strongly suggested by the auricular chondritis (sparing the lobe).</li>
                                    <li><strong>(C) VEXAS Syndrome:</strong> Strongly suggested by the combination of chondritis, systemic inflammation (fever, high CRP/ESR), erythema nodosum, and macrocytic anemia in an older male.</li>
                                    <li><strong>(E) Disseminated infection:</strong> Must be ruled out in a patient with fever and systemic symptoms.</li>
                                    <li>(A) GPA: Can cause chondritis, but less likely without upper/lower respiratory or renal involvement.</li>
                                    <li>(D) PAN: Can cause erythema nodosum and systemic inflammation, but chondritis is not typical.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Figure 1):</strong> Pre-test probability for VEXAS is higher for MALES, OLDER THAN 50 YEARS, with ELEVATED ACUTE PHASE REACTANTS presenting with typical features like auricular chondritis and macrocytic anemia.</div>`
                            },
                            {
                                text: "Initial Workup: According to the 2025 ACR Guidance Statement (Figure 1), the pre-test probability for VEXAS is high. What are the most appropriate next diagnostic steps?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. ANCA serologies (MPO/PR3)",
                                    "B. Blood cultures",
                                    "C. Empiric high-dose glucocorticoids",
                                    "D. UBA1 gene mutation testing (e.g., Sanger sequencing or NGS) on peripheral blood",
                                    "E. Bone marrow biopsy to look for vacuoles"
                                ],
                                correct: [0, 1, 3], // A, B, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) ANCA serologies:</strong> Important to rule out GPA as a mimic.</li>
                                    <li><strong>(B) Blood cultures:</strong> Essential to rule out infection before considering immunosuppression.</li>
                                    <li><strong>(D) UBA1 testing:</strong> This is the definitive diagnostic test for VEXAS.</li>
                                    <li>(C) Empiric glucocorticoids: Should generally be avoided until infection is ruled out and diagnostic testing is sent.</li>
                                    <li>(E) Bone marrow biopsy: While vacuoles are suggestive, they are neither sensitive nor specific. Genetic testing is required for diagnosis. BM biopsy is more important later for assessing MDS/cytopenias.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Figure 2):</strong> The diagnosis of VEXAS requires detection of pathogenic somatic mutations in the UBA1 gene. Testing can be performed on peripheral blood.</div>`
                            }
                        ]
                    },
                    {
                        title: "Visit 2: Diagnosis and Initial Management (4 weeks later)",
                        scenario: `<strong>Interval History:</strong> The patient was started on Prednisone 40mg daily for presumed Relapsing Polychondritis while awaiting further workup. His symptoms rapidly improved.
                        <br><br>
                        <strong>Workup Results:</strong>
                        <ul>
                            <li>ANCA: Negative.</li>
                            <li>Blood cultures: Negative.</li>
                            <li><span class="highlight">UBA1 testing (via peripheral blood Sanger sequencing): Positive for somatic mutation at p.Met41Thr.</span></li>
                        </ul>
                        <br>
                        <strong>Assessment:</strong> The diagnosis of VEXAS syndrome is confirmed. The patient's prednisone was tapered to 20mg daily, but he reports recurrence of mild ear pain and fatigue at this dose.`,
                        questions: [
                            {
                                text: "Management Principles: Now that VEXAS is confirmed, you counsel the patient. According to the 2025 ACR guidelines, which statements regarding VEXAS management are accurate?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Glucocorticoid-free remission is the usual outcome and should be the primary goal.",
                                    "B. Glucocorticoids should be tapered slowly, as small reductions in dosage can precipitate recurrence of inflammation.",
                                    "C. Patients should be managed by a multidisciplinary team, including Rheumatology and Hematology.",
                                    "D. Conventional DMARDs (e.g., Methotrexate, Azathioprine) are highly effective and preferred over targeted therapies.",
                                    "E. B-cell directed therapies (e.g., Rituximab) are contraindicated as they are not efficacious and can worsen B-cell lymphopenia."
                                ],
                                correct: [1, 2, 4], // B, C, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Slow Taper:</strong> The guidelines emphasize that "Caution should be exercised when tapering glucocorticoids, as small reductions in dosage can precipitate recurrence of inflammation."</li>
                                    <li><strong>(C) Multidisciplinary Team:</strong> The guidelines state, "Patients with VEXAS should be managed by a multidisciplinary team..." including hematologists and rheumatologists.</li>
                                    <li><strong>(E) B-cell Therapies:</strong> The guidelines explicitly state, "B cell-depleting therapies are contraindicated because they are not efficacious in VEXAS and can worsen disease-associated B cell lymphopenia."</li>
                                    <li>(A) Glucocorticoid-free remission: Incorrect. The guidelines note, "Unlike many rheumatologic diseases, glucocorticoid-free remission is unusual in VEXAS."</li>
                                    <li>(D) Conventional DMARDs: Incorrect. The guidelines state that targeted therapies (JAK inhibitors, IL-6 inhibitors) are "more effective than conventional DMARDs."</li>
                                </ul>`
                            },
                            {
                                text: "Hematologic Evaluation: Given the confirmed diagnosis of VEXAS and persistent cytopenias (anemia and thrombocytopenia), the 2025 guidelines recommend further hematologic evaluation. What steps are necessary?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Bone marrow biopsy and aspiration.",
                                    "B. Karyotyping and NGS myeloid malignancy panel on the bone marrow specimen.",
                                    "C. Immediate initiation of Azacitidine.",
                                    "D. Assessment for nutritional deficiencies (e.g., Copper, B12) that may also cause vacuoles or macrocytosis."
                                ],
                                correct: [0, 1, 3], // A, B, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) Bone marrow examination:</strong> Recommended in patients with VEXAS with associated cytopenia to exclude an associated hematologic neoplasm (MDS).</li>
                                    <li><strong>(B) Karyotype and NGS:</strong> The guidelines state these "should be performed with bone marrow examination" to identify MDS-defining abnormalities and coexisting somatic mutations.</li>
                                    <li><strong>(D) Nutritional deficiencies:</strong> Important to rule out other causes of cytopenias and macrocytosis. Copper deficiency can also cause vacuoles.</li>
                                    <li>(C) Immediate Azacitidine: Incorrect. Treatment decisions should follow a complete evaluation, including the bone marrow assessment.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Group 3):</strong> We recommend a baseline bone marrow examination in all patients with cytopenic VEXAS, including cytogenetic analysis and NGS panel targeting somatic mutations for myeloid malignancy.</div>`
                            }
                        ]
                    },
                    {
                        title: "Visit 3: Treatment Adjustments (3 months later)",
                        scenario: `<strong>Interval History:</strong> The patient continues to require Prednisone 20mg daily to control his symptoms. He has developed steroid-induced hyperglycemia.
                        <br><br>
                        <strong>Hematology Results:</strong> Bone marrow biopsy showed hypercellular marrow, prominent cytoplasmic vacuoles in myeloid and erythroid precursors, and mild dysplastic features not meeting full WHO/ICC criteria for MDS. Karyotype normal. NGS panel confirmed the UBA1 mutation and identified a <span class="highlight">TET2</span> co-mutation.
                        <br><br>
                        <strong>Assessment:</strong> Steroid-dependent VEXAS.`,
                        questions: [
                            {
                                text: "Escalation of Therapy: The patient requires ≥10mg/day of prednisone to control symptoms. According to the 2025 ACR VEXAS Treatment Algorithm (Figure 4), what are the preferred steroid-sparing agents to consider?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Methotrexate",
                                    "B. Ruxolitinib (JAK inhibitor)",
                                    "C. Tocilizumab (IL-6 inhibitor)",
                                    "D. Azathioprine",
                                    "E. Anakinra (IL-1 inhibitor)"
                                ],
                                correct: [1, 2], // B, C
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Ruxolitinib and (C) Tocilizumab:</strong> The guidelines state that medications targeting inflammatory pathways (JAK inhibitors, IL-6 inhibitors) are more effective than conventional DMARDs. Figure 4 lists Anti-IL6 and JAK inhibitors as primary steroid-sparing agents.</li>
                                    <li>(A) Methotrexate and (D) Azathioprine: Conventional DMARDs have limited efficacy.</li>
                                    <li>(E) Anakinra: IL-1 inhibitors can be considered, but the guidelines note that "severe injection site reactions have been reported from anakinra," and IL-6/JAK inhibitors are more widely used and seemingly preferred in the algorithm.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Figure 4):</strong> When patients require CS ≥ 10mg/day, the algorithm recommends starting a CS sparing agent, prioritizing Anti-IL6 or JAK inhibitors.</div>`
                            },
                            {
                                text: "Patient Education - Ruxolitinib: You decide to initiate Ruxolitinib. What key counseling points and safety measures should you discuss with the patient?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Ruxolitinib targets inflammatory pathways (JAK-STAT signaling) broadly involved in VEXAS.",
                                    "B. We must monitor your blood counts closely, as Ruxolitinib can worsen cytopenias (anemia, thrombocytopenia).",
                                    "C. This medication increases the risk of viral infections, particularly shingles (VZV) and herpes (HSV); antiviral prophylaxis should be considered.",
                                    "D. This medication is curative and will eliminate the UBA1 clone within 6 months.",
                                    "E. There is a potential increased risk of thromboembolic disease and cardiovascular events associated with this class of medication."
                                ],
                                correct: [0, 1, 2, 4], // A, B, C, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) Mechanism:</strong> JAK inhibitors target a broad spectrum of disease-relevant cytokines (e.g., IL-6, interferons).</li>
                                    <li><strong>(B) Cytopenias:</strong> The guidelines note, "Worsening cytopenia related to use of JAK inhibitors should be closely monitored and managed."</li>
                                    <li><strong>(C) Infections:</strong> Guidelines recommend considering prophylaxis for alpha herpesviruses due to the association of JAK inhibitors with increased risk for viral infections.</li>
                                    <li><strong>(E) Thrombosis/CV events:</strong> The guidelines mention the association of JAK inhibitors with these risks, advising careful patient selection.</li>
                                    <li>(D) Curative: Incorrect. Ruxolitinib manages inflammation but does not eliminate the clone. HSCT is the only curative option.</li>
                                </ul>`
                            }
                        ]
                    }
                ]
            },
            2: {
                title: "Case 2: The Hematologic Phenotype and MDS Overlap",
                patient: {
                    name: "72-year-old Male",
                    age: 72,
                    gender: "Male",
                    comorbidities: ["Type 2 Diabetes Mellitus", "Coronary Artery Disease"],
                    medications: "Metformin, Aspirin, Atorvastatin"
                },
                visits: [
                    {
                        title: "Visit 1: Initial Presentation",
                        scenario: `<strong>Chief Complaint:</strong> Worsening shortness of breath on exertion and fatigue.
                        <br><br>
                        <strong>HPI:</strong> Presents with 1 year of progressive cytopenias. He has required 4 units of pRBC transfusions over the last 3 months. He was diagnosed with presumed low-risk Myelodysplastic Syndrome (MDS) 6 months ago based on an outside bone marrow biopsy. He denies fevers, rashes, or joint pains.
                        <br><br>
                        <strong>Vitals:</strong> T 98.6°F (37.0°C), HR 88, BP 130/78.
                        <br><br>
                        <strong>Physical Exam:</strong> General: Pale, tired appearance. No acute distress.
                        <br><br>
                        <strong>Labs:</strong>
                        <ul>
                            <li>CBC: WBC 3.8 k/uL (Lymphopenia, Monocytopenia noted), Hgb <span class="lab-value">8.1</span> g/dL, MCV <span class="lab-value">112</span> fL, Platelets 95 k/uL.</li>
                            <li>Inflammatory Markers: CRP <span class="lab-value">25</span> mg/L (Mildly elevated), Ferritin <span class="lab-value">850</span> ng/mL.</li>
                            <li>B12, Folate, Copper levels: Normal.</li>
                        </ul>`,
                        questions: [
                            {
                                text: "History Taking: The patient presents with a diagnosis of MDS, profound macrocytosis, and subtle signs of inflammation. Which focused review of systems questions are most critical to ask to evaluate for potential VEXAS syndrome?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Have you experienced any pain, redness, or swelling in the cartilage of your ears or nose?",
                                    "B. Have you had any recent unexplained blood clots (DVT or PE)?",
                                    "C. Do you have a history of recurrent skin rashes, particularly painful nodules or bruise-like areas?",
                                    "D. Do you have a family history of blood disorders?",
                                    "E. Have you experienced recurrent, unexplained high fevers?"
                                ],
                                correct: [0, 1, 2, 4], // A, B, C, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) Chondritis, (C) Rashes, (E) Fevers:</strong> These are common inflammatory manifestations of VEXAS (Figure 1) and may be subtle or occur earlier in the disease course.</li>
                                    <li><strong>(B) Blood clots:</strong> Thromboembolic disease is prevalent in approximately 50% of patients with VEXAS.</li>
                                    <li>(D) Family history: Incorrect. VEXAS is caused by somatic (acquired) mutations and is not a heritable disease.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline:</strong> VEXAS presents a significant diagnostic challenge, as its clinical and laboratory features often mimic those of other established rheumatologic and hematologic diseases (like MDS). A thorough history for inflammatory symptoms is crucial.</div>`
                            },
                            {
                                text: "Diagnostic Approach: The 2025 ACR Guidance highlights that VEXAS features often mimic other hematologic diseases. What diagnostic steps are crucial at this juncture?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Repeat bone marrow examination.",
                                    "B. UBA1 genetic testing.",
                                    "C. Review of the prior bone marrow biopsy slides for cytoplasmic vacuoles.",
                                    "D. NGS myeloid panel testing (if not already done)."
                                ],
                                // Note: While repeating the BM (A) might be needed eventually, B, C, and D are the most crucial immediate steps.
                                correct: [1, 2, 3], // B, C, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) UBA1 genetic testing:</strong> Essential for diagnosis. Given the overlap with MDS, an NGS panel including UBA1 is ideal.</li>
                                    <li><strong>(C) Review prior slides:</strong> Vacuoles may have been missed or dismissed previously. The guidelines note that vacuoles in combination with relevant clinical symptoms have a high positive predictive value.</li>
                                    <li><strong>(D) NGS myeloid panel:</strong> Crucial to assess for coexisting mutations and properly classify the MDS.</li>
                                    <li>(A) Repeat bone marrow examination: May be necessary if prior samples are unavailable or inadequate, but reviewing existing data and sending UBA1 testing is the immediate priority.</li>
                                </ul>`
                            }
                        ]
                    },
                    {
                        title: "Visit 2: Diagnostic Confirmation and Reclassification (3 weeks later)",
                        scenario: `<strong>Interval History:</strong> Upon closer questioning, the patient admits to intermittent low-grade fevers and a history of two unprovoked DVTs 5 years ago.
                        <br><br>
                        <strong>Workup Results:</strong>
                        <ul>
                            <li><span class="highlight">UBA1 testing (via peripheral blood NGS): Positive for somatic mutation (p.Met41Leu).</span></li>
                            <li>Repeat Bone Marrow Examination: Hypercellular marrow (80%). Increased myeloid-to-erythroid ratio. Prominent cytoplasmic vacuoles in erythroid and myeloid precursors. Dysplasia noted in erythroid and myeloid lineages. Blasts <5%.</li>
                            <li>Cytogenetics: Normal Karyotype (46, XY).</li>
                            <li>NGS Myeloid Panel: UBA1 mutation confirmed. Co-mutations in <span class="highlight">DNMT3A</span> and <span class="highlight">TET2</span>. No other driver mutations.</li>
                        </ul>
                        <br>
                        <strong>Assessment:</strong> VEXAS syndrome confirmed.`,
                        questions: [
                            {
                                text: "Bone Marrow Interpretation and MDS Diagnosis: According to the 2025 ACR guidelines, how should these bone marrow findings be interpreted in the context of VEXAS?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. The presence of vacuoles confirms the diagnosis of MDS in a patient with cytopenias.",
                                    "B. Interpretation of bone marrow is challenging, as VEXAS itself frequently causes signs of dysplasia without meeting criteria for MDS.",
                                    "C. In VEXAS, assessment of dysplasia should require morphologic evidence other than the presence of vacuolization alone.",
                                    "D. Mutations in DNMT3A and TET2 are common in VEXAS and likely reflect clonal hematopoiesis rather than definitive MDS.",
                                    "E. Given the significant transfusion-dependent anemia and morphologic dysplasia, an associated diagnosis of MDS should still be strongly considered."
                                ],
                                correct: [1, 2, 3, 4], // B, C, D, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Challenging Interpretation:</strong> The guidelines state this explicitly due to the overlap in features.</li>
                                    <li><strong>(C) Dysplasia beyond vacuoles:</strong> Vacuolization is ubiquitous in VEXAS and should not be the sole criterion for dysplasia.</li>
                                    <li><strong>(D) DNMT3A/TET2:</strong> The guidelines note the somatic clonal landscape in VEXAS is dominated by these mutations, irrespective of an MDS diagnosis.</li>
                                    <li><strong>(E) Considering MDS:</strong> The guidelines reference recent literature employing stringent criteria for MDS, requiring significant/persistent cytopenia (like transfusion dependence) along with morphologic/genetic findings. This patient may meet these criteria.</li>
                                    <li>(A) Vacuoles confirm MDS: Incorrect. Vacuoles are characteristic of VEXAS but not diagnostic of MDS.</li>
                                </ul>`
                            },
                            {
                                text: "Management of Hematologic Phenotype: The patient has minimal inflammatory symptoms but severe hematologic manifestations (transfusion-dependent bone marrow failure). How should this patient be managed according to the 2025 guidelines (Figure 4)?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Initiate high-dose glucocorticoids (1mg/kg) immediately.",
                                    "B. Initiate Ruxolitinib (JAK inhibitor) to control inflammation and improve counts.",
                                    "C. Consider medications that reduce or eliminate the clonal burden of disease (e.g., Azacitidine).",
                                    "D. Evaluate the patient as a candidate for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)."
                                ],
                                correct: [2, 3], // C, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(C) Azacitidine:</strong> The guidelines support the use of Azacitidine, noting it has demonstrated reduction or elimination of UBA1 mutation burden.</li>
                                    <li><strong>(D) HSCT:</strong> HSCT is a curative option. The guidelines state patients with progressive and severe bone marrow failure (e.g., transfusion-dependent) are candidates.</li>
                                    <li>(A) High-dose glucocorticoids: Primarily used for inflammatory manifestations, which are minimal here.</li>
                                    <li>(B) Ruxolitinib: Primarily used for inflammatory manifestations and may worsen cytopenias.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Figure 4):</strong> For patients with Hematologic Manifestations (Moderate to Severe Cytopenia, Transfusion dependent, MDS), the algorithm directs towards evaluating for HSCT candidacy and considering Azacitidine.</div>`
                            }
                        ]
                    },
                    {
                        title: "Visit 3: Treatment Response (6 months later)",
                        scenario: `<strong>Interval History:</strong> The patient was started on Azacitidine by Hematology. After 6 cycles, he is now transfusion-independent, and his inflammatory markers have normalized.
                        <br><br>
                        <strong>Labs:</strong> Hgb <span class="lab-value">10.5</span> g/dL, MCV <span class="lab-value">100</span> fL, CRP <5 mg/L. Repeat UBA1 testing shows a significant reduction in the Variant Allele Fraction (VAF).`,
                        questions: [
                            {
                                text: "Patient Education - Azacitidine: The patient asks how Azacitidine works for his condition. Based on the 2025 guidelines, how do you explain the mechanism and efficacy of Azacitidine in VEXAS?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Azacitidine directly inhibits IL-6 and JAK-STAT signaling, controlling inflammation.",
                                    "B. Azacitidine is a hypomethylating agent commonly used to treat MDS.",
                                    "C. Azacitidine can reduce or eliminate the clonal burden of disease (the cells harboring the UBA1 mutation).",
                                    "D. Improvement in inflammation often coincides with the reduction of the UBA1 mutation burden.",
                                    "E. Successful therapy cessation with sustained remission has been reported in small case reports, but long-term data are lacking."
                                ],
                                correct: [1, 2, 3, 4], // B, C, D, E
                                explanation: `<strong>Rationale:</strong> All these points (B, C, D, E) are directly supported by the 2025 guidelines in the section discussing medications that reduce clonal burden.
                                <br><br>
                                (A) is incorrect as Azacitidine is a hypomethylating agent, not a direct cytokine inhibitor.
                                <div class="new-guideline"><strong>2025 Guideline:</strong> Preliminary data on the use of azacytidine... has demonstrated reduction or elimination of UBA1 mutation burden... in conjunction with improvement in inflammation.</div>`
                            }
                        ]
                    }
                ]
            },
            3: {
                title: "Case 3: Diagnostic Challenges and Complications",
                patient: {
                    name: "62-year-old Female",
                    age: 62,
                    gender: "Female",
                    comorbidities: ["Hypothyroidism"],
                    medications: "Levothyroxine, Prednisone 20mg daily"
                },
                visits: [
                    {
                        title: "Visit 1: The Vasculitis Mimic",
                        scenario: `<strong>Chief Complaint:</strong> Recurrent fevers, rash, and shortness of breath.
                        <br><br>
                        <strong>HPI:</strong> Presents with 9 months of systemic symptoms. She initially developed severe muscle pain and stiffness, diagnosed as Polymyalgia Rheumatica (PMR), and started on Prednisone. Over the last 3 months, despite being on Prednisone 20mg daily, she developed recurrent fevers, non-infectious periorbital swelling, and a painful, purpuric rash on her lower extremities.
                        <br><br>
                        <strong>Vitals:</strong> T 101.3°F (38.5°C), HR 100, BP 140/90.
                        <br><br>
                        <strong>Physical Exam:</strong>
                        <ul>
                            <li>HEENT: Bilateral periorbital edema, non-tender.</li>
                            <li>Skin: Palpable purpura on bilateral lower legs and feet.</li>
                        </ul>
                        <br>
                        <strong>Labs:</strong>
                        <ul>
                            <li>Hgb 11.5 g/dL, MCV <span class="lab-value">102</span> fL.</li>
                            <li>CRP <span class="lab-value">150</span> mg/L; ESR <span class="lab-value">90</span> mm/hr.</li>
                            <li>ANCA, ANA, RF, CCP: Negative.</li>
                        </ul>
                        <div class="clinical-note">A skin biopsy confirms leukocytoclastic vasculitis (LCV).</div>`,
                        questions: [
                            {
                                text: "Diagnostic Considerations: The constellation of symptoms raises suspicion for VEXAS syndrome, even though the patient is female. According to the 2025 guidelines, what factors support considering VEXAS in this patient?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. VEXAS is exclusively found in males due to the X-linked nature of the UBA1 gene.",
                                    "B. The clinical features (fevers, LCV, periorbital swelling) are typical inflammatory manifestations of VEXAS.",
                                    "C. Macrocytosis is a common hematologic abnormality.",
                                    "D. VEXAS has been reported in women, particularly those with X chromosome abnormalities (e.g., monosomy X).",
                                    "E. The initial presentation phenocopies other rheumatologic diseases (like PMR) but evolves with atypical features and treatment resistance."
                                ],
                                correct: [1, 2, 3, 4], // B, C, D, E
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Clinical Features:</strong> Fevers, LCV, and periorbital swelling are listed as typical disease features in Figure 1.</li>
                                    <li><strong>(C) Macrocytosis:</strong> A common hematologic feature.</li>
                                    <li><strong>(D) Females:</strong> The guidelines explicitly mention: "The vast majority of patients identified are male... although VEXAS has been reported in women, particularly those with monosomy X."</li>
                                    <li><strong>(E) Mimicry and Resistance:</strong> The guidelines note that patients often carry specific rheumatologic diagnoses (like PMR) but their course is atypical regarding severity and response to treatment.</li>
                                    <li>(A) Exclusively male: Incorrect, as noted above.</li>
                                </ul>`
                            },
                            {
                                text: "Diagnostic Strategy: You decide to test for VEXAS. What is a reasonable initial diagnostic approach according to the guidelines?",
                                note: "(Select One)",
                                type: "single",
                                options: [
                                    "A. Bone marrow biopsy looking for vacuoles; genetic testing is not required if vacuoles are present.",
                                    "B. Targeted testing for UBA1 exon 3 variants (e.g., Sanger sequencing) on peripheral blood.",
                                    "C. Whole-exome sequencing on skin biopsy tissue.",
                                    "D. Flow cytometry for vacuolated myeloid cells only."
                                ],
                                correct: 1, // B
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(B) Targeted testing on peripheral blood:</strong> The guidelines suggest that as an initial diagnostic approach, low-cost genetic testing, such as exon 3 analysis by Sanger sequencing, can be used, typically using DNA from peripheral blood.</li>
                                    <li>(A) Bone marrow vacuoles: Incorrect. Genetic testing is always required for diagnosis.</li>
                                    <li>(C) WES on skin: Incorrect. WES is broader than necessary initially, and skin tissue tends to have lower mutation levels.</li>
                                    <li>(D) Flow cytometry: Can be helpful adjunctively but is not the primary diagnostic modality.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Figure 2):</strong> The algorithm suggests starting with UBA1 exon 3 genotyping (e.g., by Sanger sequencing) on peripheral blood or bone marrow.</div>`
                            }
                        ]
                    },
                    {
                        title: "Visit 2: Interpreting Negative Results (4 weeks later)",
                        scenario: `<strong>Interval History:</strong> The patient's prednisone was increased to 40mg daily with improvement in symptoms.
                        <br><br>
                        <strong>Workup Results:</strong> Peripheral blood Sanger sequencing for UBA1 exon 3 variants returned <span class="highlight">negative</span>.
                        <br><br>
                        <strong>Assessment:</strong> The attending physician suggests VEXAS is ruled out and recommends initiating Methotrexate for presumed vasculitis.`,
                        questions: [
                            {
                                text: "Diagnostic Challenges: The resident recalls the limitations of genetic testing discussed in the 2025 VEXAS guidelines (Figure 2). Which factors could explain a negative Sanger sequencing result despite the patient having VEXAS?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. Sanger sequencing lacks sensitivity to detect somatic variants with low Variant Allele Fraction (VAF) (typically <15-20%).",
                                    "B. The patient may have a UBA1 mutation outside of exon 3.",
                                    "C. Active treatment (e.g., hypomethylating agents) may decrease the mutation level, affecting accuracy.",
                                    "D. The mutation may be present at a higher VAF in the bone marrow than in the peripheral blood."
                                ],
                                correct: [0, 1, 2, 3], // A, B, C, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) Low VAF:</strong> Sanger sequencing can identify mutations with VAFs roughly above 20% but lacks sensitivity for lower mutational burden.</li>
                                    <li><strong>(B) Outside Exon 3:</strong> While most mutations are in exon 3, mutations outside this region have been reported.</li>
                                    <li><strong>(C) Active treatment:</strong> The guidelines note that detection may be compromised by certain treatments, particularly hypomethylating agents (though this patient is only on steroids, it is a recognized limitation of testing mentioned in the guidelines).</li>
                                    <li><strong>(D) BM vs PB:</strong> There are isolated cases where mutations are detected at much higher VAFs in the bone marrow.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Group 2):</strong> Targeted testing for exon 3 variants... may miss somatic variants with low VAF (Sanger sequencing) or variants outside of exon 3.</div>`
                            },
                            {
                                text: "Next Steps in Investigation: Clinical suspicion for VEXAS remains high. What is the most appropriate next step to confirm or exclude the diagnosis?",
                                note: "(Select One)",
                                type: "single",
                                options: [
                                    "A. Proceed with Methotrexate and monitor clinical response.",
                                    "B. Repeat peripheral blood Sanger sequencing in 3 months.",
                                    "C. Perform a bone marrow examination with Next-Generation Sequencing (NGS) testing for UBA1 (covering the complete gene) and karyotyping.",
                                    "D. Perform a renal biopsy to evaluate for pauci-immune vasculitis."
                                ],
                                correct: 2, // C
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(C) BM with NGS and Karyotyping:</strong> If clinical suspicion is high and initial testing is negative, the guidelines recommend ensuring testing covers the complete gene (using sensitive methods like NGS) and considering testing a bone marrow sample. Karyotyping is also crucial in a female patient to look for Monosomy X.</li>
                                    <li>(A) Methotrexate: Inappropriate to start therapy for a mimic when the primary diagnosis is still suspected.</li>
                                    <li>(B) Repeat Sanger: Unlikely to yield different results; a more sensitive method is needed.</li>
                                    <li>(D) Renal biopsy: Not indicated based on current labs.</li>
                                </ul>
                                <div class="new-guideline"><strong>2025 Guideline (Group 2):</strong> If clinical suspicion is high and genetic testing... is negative on the peripheral blood, clinicians should ensure that testing covers the complete gene and consider testing a bone marrow sample.</div>`
                            }
                        ]
                    },
                    {
                        title: "Visit 3: Confirmation and Complications (3 months later)",
                        scenario: `<strong>Workup Results:</strong>
                        <ul>
                            <li>Bone Marrow Examination: Vacuoles present.</li>
                            <li>Karyotype: <span class="highlight">45, X [15] / 46, XX [5] (Monosomy X in 75% of cells).</span></li>
                            <li>NGS (Bone Marrow): <span class="highlight">UBA1 p.Met41Val mutation detected. VAF 10%.</span></li>
                        </ul>
                        <br>
                        <strong>Assessment:</strong> VEXAS syndrome confirmed. Monosomy X explains the phenotype in a female patient. The low VAF (10%) explains the negative Sanger sequencing.
                        <br><br>
                        <strong>Interval History:</strong> The patient was started on Ruxolitinib (JAK inhibitor) and PJP/VZV prophylaxis. Her inflammation improved, and prednisone was tapered to 10mg. She now presents urgently with acute onset left leg swelling and pain.
                        <br><br>
                        <strong>Exam:</strong> Left lower extremity is erythematous, warm, and swollen.
                        <div class="clinical-note">Ultrasound confirms an acute deep vein thrombosis (DVT).</div>`,
                        questions: [
                            {
                                text: "Acute Complication: Which statements regarding thromboembolic disease (VTE) in VEXAS are correct according to the 2025 guidelines?",
                                note: "(Select All That Apply)",
                                type: "multiple",
                                options: [
                                    "A. VTE is prevalent in approximately 50% of patients with VEXAS.",
                                    "B. Thromboembolic events typically occur in association with ongoing disease activity (inflammation).",
                                    "C. Patients with VEXAS should receive thromboprophylaxis in high-risk settings (e.g., hospitalization).",
                                    "D. The use of JAK inhibitors may further increase the risk of thromboembolic disease.",
                                    "E. The duration and choice of anticoagulation therapy for VEXAS-associated thrombosis are clearly defined in the guidelines."
                                ],
                                correct: [0, 1, 2, 3], // A, B, C, D
                                explanation: `<strong>Rationale:</strong>
                                <ul>
                                    <li><strong>(A) Prevalence:</strong> The guidelines state VTE is prevalent in approx 50% of patients.</li>
                                    <li><strong>(B) Disease Activity:</strong> Thrombosis typically occurs "in association with ongoing disease activity."</li>
                                    <li><strong>(C) Prophylaxis:</strong> The guidelines recommend thromboprophylaxis in high-risk settings.</li>
                                    <li><strong>(D) JAK inhibitors:</strong> The guidelines note the association of JAK inhibitors and increased risk for thromboembolic disease.</li>
                                    <li>(E) Defined duration: Incorrect. The guidelines state that the "duration and choice of anticoagulation therapy has not been defined."</li>
                                </ul>`
                            }
                        ]
                    }
                ]
            }
        };

        // --- Core Functions ---

        function openLink(url) {
            window.open(url, '_blank');
        }

        function selectCase(caseNum) {
            if (!cases[caseNum]) {
                console.error('Case not found:', caseNum);
                return;
            }
            
            currentCase = caseNum;
            currentVisit = 0;
            score = 0;
            totalQuestions = 0;
            selections = {};
            
            // Count total questions
            cases[caseNum].visits.forEach(visit => {
                totalQuestions += visit.questions.length;
            });
            
            // Update button states
            updateCaseButtons(caseNum);
            
            loadCaseIntro();
        }

        function updateCaseButtons(activeCaseNum) {
            document.querySelectorAll('.case-btn').forEach((btn, index) => {
                const caseNum = index + 1;
                btn.classList.remove('active');
                if (completedCases.has(caseNum)) {
                    btn.classList.add('completed');
                }
                if (caseNum === activeCaseNum) {
                    btn.classList.add('active');
                }
            });
        }

        function loadCaseIntro() {
            const caseData = cases[currentCase];
            const content = document.getElementById('content');
            
            // Ensure occupation is displayed if present, otherwise omit
            const occupationHtml = caseData.patient.occupation ? `<div class="info-item"><strong>Occupation:</strong> ${caseData.patient.occupation}</div>` : '';

            content.innerHTML = `
                <div class="case-intro">
                    <h2>${caseData.title}</h2>
                    <div class="patient-info">
                        <h3>Patient Information</h3>
                        <div class="info-grid">
                            <div class="info-item"><strong>Patient:</strong> ${caseData.patient.name}</div>
                            <div class="info-item"><strong>Age:</strong> ${caseData.patient.age} years old</div>
                            <div class="info-item"><strong>Gender:</strong> ${caseData.patient.gender}</div>
                            ${occupationHtml}
                        </div>
                        <div style="margin-top: 15px;">
                            <div class="info-item"><strong>Comorbidities:</strong> ${caseData.patient.comorbidities.join(', ')}</div>
                            <div class="info-item"><strong>Current Medications:</strong> ${caseData.patient.medications}</div>
                        </div>
                    </div>
                    <button class="submit-btn" onclick="startCase()">Begin Case</button>
                </div>
            `;
        }

        function startCase() {
            if (!currentCase || !cases[currentCase]) {
                console.error('No case selected');
                return;
            }
            loadVisit();
        }

        function loadVisit() {
            const caseData = cases[currentCase];
            const visit = caseData.visits[currentVisit];
            const content = document.getElementById('content');
            selections = {}; // Reset selections for the new visit
            
            let questionsHtml = '';
            visit.questions.forEach((question, qIndex) => {
                const questionId = `q${currentVisit}_${qIndex}`;
                selections[questionId] = []; // Initialize selections array for this question

                questionsHtml += `
                    <div class="question-box" id="${questionId}">
                        <h4>Question ${currentVisit + 1}.${qIndex + 1}: ${question.text}</h4>
                        ${question.note ? `<div class="question-note">${question.note}</div>` : ''}
                        <div class="options">
                            ${question.options.map((option, oIndex) => `
                                <button class="option" onclick="selectOption('${questionId}', ${oIndex}, '${question.type}')" id="${questionId}_opt${oIndex}">
                                    ${option}
                                </button>
                            `).join('')}
                        </div>
                        <button class="submit-btn" id="${questionId}_submit" onclick="submitAnswer('${questionId}', ${qIndex})" disabled>Submit Answer</button>
                        <div class="feedback" id="${questionId}_feedback"></div>
                    </div>
                `;
            });
            
            content.innerHTML = `
                <div class="visit-section" id="visitSection">
                    <div class="visit-header">
                        <h3>${visit.title}</h3>
                        <p>Visit ${currentVisit + 1} of ${caseData.visits.length}</p>
                    </div>
                    
                    <div class="clinical-data">
                        <h4>Clinical Presentation</h4>
                        <div>${visit.scenario}</div>
                    </div>
                    
                    ${questionsHtml}
                    
                    <button class="next-btn" id="nextBtn" onclick="nextVisit()">Continue →</button>
                </div>
                
                <div class="case-complete" id="caseComplete">
                    <h3>🎉 Case Complete!</h3>
                    <div class="score-display">Your Score: <span id="finalScore"></span></div>
                    <div class="final-feedback" id="finalFeedback"></div>
                </div>
            `;
        }

        function selectOption(questionId, optionIndex, type) {
            const currentSelections = selections[questionId] || [];
            
            if (type === 'single') {
                // Single choice
                document.querySelectorAll(`#${questionId} .option`).forEach(opt => {
                    opt.classList.remove('selected');
                });
                document.getElementById(`${questionId}_opt${optionIndex}`).classList.add('selected');
                selections[questionId] = [optionIndex];
            } else {
                // Multiple choice
                const opt = document.getElementById(`${questionId}_opt${optionIndex}`);
                if (opt.classList.contains('selected')) {
                    opt.classList.remove('selected');
                    const index = currentSelections.indexOf(optionIndex);
                    if (index > -1) currentSelections.splice(index, 1);
                } else {
                    opt.classList.add('selected');
                    currentSelections.push(optionIndex);
                }
                selections[questionId] = currentSelections;
            }
            
            // Enable submit button if at least one option selected
            const hasSelection = selections[questionId].length > 0;
            document.getElementById(`${questionId}_submit`).disabled = !hasSelection;
        }

        function submitAnswer(questionId, questionIndex) {
            const visit = cases[currentCase].visits[currentVisit];
            const question = visit.questions[questionIndex];
            const selectedIndices = selections[questionId] || [];
            
            if (selectedIndices.length === 0) return;
            
            let isCorrect = false;
            let isPartial = false;
            
            // Evaluate the answer
            if (question.type === 'single') {
                isCorrect = selectedIndices[0] === question.correct;
            } else {
                const correctSet = new Set(question.correct);
                const selectedSet = new Set(selectedIndices);
                
                if (correctSet.size === selectedSet.size && 
                    [...correctSet].every(x => selectedSet.has(x))) {
                    isCorrect = true;
                } else if ([...selectedSet].some(x => correctSet.has(x))) {
                    isPartial = true; // Award partial credit if some correct options are selected
                }
            }
            
            // Update score
            if (isCorrect) score++;
            else if (isPartial) score += 0.5;
            
            // Visual feedback on options
            document.querySelectorAll(`#${questionId} .option`).forEach((opt, index) => {
                opt.onclick = null; // Disable further clicks
                opt.style.cursor = 'default';
                // Remove interaction classes
                opt.classList.remove('selected');
                opt.style.transform = 'none';

                
                const isSelected = selectedIndices.includes(index);
                const isCorrectAnswer = question.type === 'single' ? index === question.correct : question.correct.includes(index);

                if (isCorrectAnswer) {
                    opt.classList.add('correct');
                } else if (isSelected) {
                    opt.classList.add('incorrect');
                }
            });
            
            // Show detailed feedback box
            const feedback = document.getElementById(`${questionId}_feedback`);
            let feedbackClass, feedbackTitle;

            if (isCorrect) {
                feedbackClass = 'correct';
                feedbackTitle = '✓ Correct!';
            } else if (isPartial) {
                feedbackClass = 'partial';
                feedbackTitle = '⚠ Partially Correct';
            } else {
                feedbackClass = 'incorrect';
                feedbackTitle = '✗ Incorrect';
            }

            feedback.className = `feedback ${feedbackClass}`;
            feedback.innerHTML = `
                <h5>${feedbackTitle}</h5>
                <div>${question.explanation}</div>
            `;
            feedback.style.display = 'block';
            
            // Hide submit button
            document.getElementById(`${questionId}_submit`).style.display = 'none';
            
            // Check if all questions in visit are answered
            checkVisitComplete();
        }

        function checkVisitComplete() {
            const visit = cases[currentCase].visits[currentVisit];
            const allAnswered = visit.questions.every((_, qIndex) => {
                const qId = `q${currentVisit}_${qIndex}`;
                const feedbackEl = document.getElementById(`${qId}_feedback`);
                return feedbackEl && feedbackEl.style.display === 'block';
            });
            
            if (allAnswered) {
                const nextBtn = document.getElementById('nextBtn');
                nextBtn.style.display = 'block';
                // Update button text if it's the last visit
                if (currentVisit === cases[currentCase].visits.length - 1) {
                    nextBtn.textContent = 'Finish Case and View Score →';
                }
            }
        }

        function nextVisit() {
            currentVisit++;
            
            if (currentVisit < cases[currentCase].visits.length) {
                loadVisit();
            } else {
                showCaseComplete();
            }
        }

        function showCaseComplete() {
            const caseComplete = document.getElementById('caseComplete');
            // Adjust score calculation for partial credits
            const percentage = Math.round((score / totalQuestions) * 100);
            
            // Hide visit section
            document.getElementById('visitSection').style.display = 'none';
            
            // Show completion
            caseComplete.style.display = 'block';
            document.getElementById('finalScore').textContent = `${score.toFixed(1)}/${totalQuestions} (${percentage}%)`;
            
            // Generate final feedback
            let feedbackHtml = '<h4>Case Summary & Key Learning Points</h4>';
            
            if (percentage >= 90) {
                feedbackHtml += '<p><strong>Excellent work!</strong> You demonstrated mastery of the 2025 VEXAS guidelines.</p>';
            } else if (percentage >= 70) {
                feedbackHtml += '<p><strong>Good performance!</strong> You showed solid understanding of VEXAS syndrome. Review the guidelines for areas where you lost points.</p>';
            } else {
                feedbackHtml += '<p><strong>Review recommended.</strong> Consider revisiting the 2025 VEXAS guidelines to solidify your understanding.</p>';
            }
            
            // Add key points based on the case
            feedbackHtml += '<div class="key-points"><h4>Critical VEXAS Guidelines from This Case:</h4><ul>';
            
            if (currentCase === 1) {
                feedbackHtml += `
                    <li><span class="highlight">Classic Features:</span> Male >50, auricular chondritis, macrocytic anemia, elevated inflammatory markers (Figure 1).</li>
                    <li><span class="highlight">Diagnosis:</span> UBA1 testing on peripheral blood is the preferred initial test (Figure 2).</li>
                    <li><span class="highlight">Management:</span> Multidisciplinary care (Rheum/Heme) is essential. Glucocorticoid-free remission is unusual.</li>
                    <li><span class="highlight">Steroid-sparing:</span> JAK inhibitors (e.g., Ruxolitinib) and IL-6 inhibitors are preferred over conventional DMARDs (Figure 4).</li>
                    <li><span class="highlight">Contraindications:</span> B-cell depletion (e.g., Rituximab) is contraindicated.</li>
                `;
            } else if (currentCase === 2) {
                feedbackHtml += `
                    <li><span class="highlight">Hematologic Phenotype:</span> VEXAS can mimic MDS with minimal overt inflammation; look for subtle clues (macrocytosis, elevated ferritin, history of VTE).</li>
                    <li><span class="highlight">Bone Marrow Interpretation:</span> Challenging; vacuoles and dysplasia are common in VEXAS itself. DNMT3A/TET2 mutations are frequent.</li>
                    <li><span class="highlight">MDS Diagnosis:</span> Requires stringent criteria (e.g., transfusion dependence + morphology/genetics) beyond just vacuoles.</li>
                    <li><span class="highlight">Clone-directed Therapy:</span> For hematologic phenotype, consider Azacitidine to reduce UBA1 burden (Figure 4).</li>
                    <li><span class="highlight">HSCT:</span> Only curative option; evaluate patients with severe bone marrow failure (Figure 4).</li>
                `;
            } else if (currentCase === 3) {
                feedbackHtml += `
                    <li><span class="highlight">Female VEXAS:</span> Rare but possible, particularly with X chromosome abnormalities (e.g., Monosomy X).</li>
                    <li><span class="highlight">Diagnostic Pitfalls:</span> Negative Sanger sequencing does not exclude VEXAS due to low VAF (<15-20%) or non-exon 3 mutations (Figure 2).</li>
                    <li><span class="highlight">Next Steps:</span> If suspicion remains high, proceed to BM with NGS (more sensitive) and karyotyping.</li>
                    <li><span class="highlight">Thrombosis:</span> High prevalence (~50%), associated with active disease. Prophylaxis needed in high-risk settings.</li>
                    <li><span class="highlight">JAK Inhibitors & VTE:</span> JAK inhibitors may further increase thrombosis risk.</li>
                `;
            }
            
            feedbackHtml += '</ul></div>';
            
            feedbackHtml += `
                <div style="margin-top: 30px; text-align: center;">
                    <button class="submit-btn" onclick="resetToMenu()">Return to Case Selection</button>
                </div>
            `;
            
            document.getElementById('finalFeedback').innerHTML = feedbackHtml;
            
            // Mark case as completed
            completedCases.add(currentCase);
            updateCaseButtons(null);
        }

        function resetToMenu() {
            currentCase = null;
            const content = document.getElementById('content');
            content.innerHTML = `
                <div class="welcome">
                    <h2>Select Another Case</h2>
                    <p>Choose a case above to continue learning the 2025 ACR VEXAS guidelines.</p>
                    <div class="key-points" style="max-width: 600px; margin: 30px auto;">
                        <h4>Progress Summary</h4>
                        <ul style="text-align: left;">
                            ${[1, 2, 3].map(caseNum => {
                                const completed = completedCases.has(caseNum);
                                return `<li>Case ${caseNum}: ${completed ? '✓ Completed' : 'Incomplete'}</li>`;
                            }).join('')}
                        </ul>
                    </div>
                    <div class="key-points" style="max-width: 600px; margin: 30px auto;">
                        <h4>Key 2025 VEXAS Guideline Themes</h4>
                        <ul style="text-align: left;">
                            <li><strong>Diagnosis:</strong> High suspicion needed; UBA1 testing essential (NGS preferred if initial Sanger is negative).</li>
                            <li><strong>Phenotypes:</strong> Recognize both Inflammatory (Chondritis, Vasculitis) and Hematologic (MDS, Bone Marrow Failure) presentations.</li>
                            <li><strong>Management:</strong> Requires Multidisciplinary care (Rheumatology + Hematology).</li>
                            <li><strong>Treatment:</strong> JAK inhibitors/IL-6 inhibitors for inflammation; Azacitidine/HSCT for hematologic/clonal burden.</li>
                        </ul>
                    </div>
                </div>
            `;
            
            // Update button states
            updateCaseButtons(null);
        }

    </script>
</body>
</html>